Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma - 31/03/23
Highlights |
• | Trop-2 is consistently overexpressed in pancreatic ductal adenocarcinomas. |
• | With Trop-2 expression evaluated both at the transcriptomic and protein level. |
• | mRNA expression maintained between primary and metastatic lesions. |
• | No association with pathological features or survival outcomes. |
Abstract |
Background |
Trop-2 is overexpressed in tumor cells of various cancers, including pancreatic ductal adenocarcinoma (PDAC), and has emerged as a potent therapeutic target. We evaluated Trop-2 expression both at the transcriptomic and protein levels, and its correlation with tumor features and patients’ outcomes in a large cohort of PDAC.
Methods |
We included patients undergoing pancreatic resection for PDAC in 5 academic hospitals in France and Belgium. Transcriptomic profiles were obtained from FFPE tissue samples, with paired primary -25and metastatic lesions when available. Protein expression was evaluated by immunohistochemistry (IHC) using tissue micro-arrays.
Results |
495 patients (male 54%, median age 63 years) were included between 1996 and 2012. Trop-2 mRNA expression was significantly associated to tumor cellularity, but no association with survival nor with any clinical or pathological features was observed, with tumor cells showing an overall high expression among every subgroup. Trop-2 mRNA expression was maintained between primary and metastatic lesion in all 26 paired samples evaluated. In 50 tumors assessed by IHC, 30%, 68% and 2% harbored a high, medium, or low Trop-2 expression score, respectively. Trop-2 staining was significantly associated to mRNA expression, but not to survival or any pathological features.
Conclusions |
Our results suggest Trop-2 overexpression as a ubiquitous marker of PDAC tumor cells and thus a promising therapeutic target to evaluate in these patients.
Le texte complet de cet article est disponible en PDF.Keywords : Trop-2, Pancreatic ductal adenocarcinoma, PDAC, Antibody-drug conjugate
Plan
Vol 47 - N° 4
Article 102108- avril 2023 Retour au numéro
Article précédent
- Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score–Matched case-control analysis
- Anaïs Jenvrin, Athéna Galletto-Pregliasco, Etienne Audureau, Anaïs Pujals, Loëtitia Favre, Alain Luciani, Julien Calderaro, Daniele Sommacale, Gilles Chatellier, Christophe Tournigand, Alexis Laurent, Emmanuelle Kempf
- Risk of post-ERCP pancreatitis is increased in patients with end-stage renal disease – a meta-analysis
- Suprabhat Giri, Kailash Kolhe, Sridhar Sundaram
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?